LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre study
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70160 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Hengrui Liang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disea…. Hauptthemen laut MEDLINE: Lung Neoplasms, Proteomics, Biomarkers, Tumor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratory, Grant R&D Program of Guangzhou National, National Key R&D Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Plasma protein has gained prominence in the non‐invasive predicting of lung cancer. We utilised Zeolite Zotero NaY‐based plasma proteomics to investigate its potential for multiple event predicting, including lung cancer diagnosis (task #1), lymph node metastasis detection (task #2) and tumour‒node‒metastasis (TNM) staging (task #3).
Methods
A total of 4703 plasma proteins were quantified from 241 participants based on a prospective cohort of 2757 participants. An additional 46 participants from external prospective cohort of 735 participants were used for validation. Feature selection was performed using differential expressed protein analysis, area under curve (AUC) evaluation and least absolute shrinkage and selection operator (LASSO) regression. Random forest was used for multitask model construction based on the key proteins. Feature importance was interpreted using Shapley additive explanations (SHAP) algorithm.
Results
For task #1, 10 proteins panel showed an AUC of .87 (.77‒.97) in the external validation. After integrating clinical factors, a significant increase diagnostic accuracy was observed with AUC of .91 (.85‒.98). For task #2, nine proteins panel achieved an AUC of .88 (.80‒.96), integration model showed an increase diagnostic accuracy with AUC of .90 (.85‒.97). For task #3, 10 proteins panel showed an AUC of .88 (.74‒.96) for stage I, .92 (.84‒.97) for stage II, .88 (.76‒.96) for stage III and .99 (.98‒.99) for stage IV in the integration model.
Conclusions
This study comprehensively profiled the NaY‐based plasma proteome biomarker, laying the foundation for a high‐performance blood test for predicting multiple events in lung cancer. Key points Our study developed an innovative nanomaterial, Zeolite NaY, which addressed the masking effect and improved the depth of the proteome. The performance of NaY‐based plasma proteomics as a preclinical diagnostic tool was validated through both internal and external cohort. Furthermore, we explored the different patterns of plasma protein changes during the progression of lung cancer and used the explanations method to elucidate the roles of proteins in the multitask predictive model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangz…
- Department of Proteomics, Tianjin Key Laboratory of Clinical Multi-Omics, Tianjin, China.
ORCID-Profile: Runchen Wang, Yu Jiang, Wenhua Liang
Förderung
- Laboratory, Grant R&D Program of Guangzhou National
- National Key R&D Program of China
- National Natural Science Foundation of China
- Grant of State Key Laboratory of Respiratory Disease
- National Key Research and Development Program of China
Zitieren
APA
Liang, H., Wang, R., Cheng, R., Ye, Z., Zhao, N., Zhao, X., Huang, Y., Jiang, Z., Li, W., Zheng, J., Deng, H., Jiang, Y., Lin, Y., Yan, Y., Song, L., Li, J., Xu, X., Liang, W., Liu, J., & He, J. (2025). LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre study. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70160
Vancouver
Liang H, Wang R, Cheng R, Ye Z, Zhao N, Zhao X, et al. LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre study. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70160
BibTeX
@article{Liang2025,
author = {Liang, Hengrui and Wang, Runchen and Cheng, Ran and Ye, Zhiming and Zhao, Na and Zhao, Xiaohong and Huang, Ying and Jiang, Zhanpeng and Li, Wangzhong and Zheng, Jianqi and Deng, Hongsheng and Jiang, Yu and Lin, Yuechun and Yan, Yun and Song, Lei and Li, Jie and Xu, Xin and Liang, Wenhua and Liu, Jun and He, Jianxing},
title = {LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre study},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70160}
}
EUVIMED